| Abbreviations |
|
3 | (2) |
|
Clinical Approach to Initial Choice of Antimicrobial Therapy |
|
|
5 | (58) |
|
Prophylaxis and Treatment of Organisms of Potential Use as Biological Weapons |
|
|
61 | (2) |
|
Recommended Antimicrobial Agents Against Selected Bacteria |
|
|
63 | (3) |
|
Suggested Duration of Antibiotic Therapy in Immunocompetent Patients |
|
|
66 | (1) |
|
Comparison of Antimicrobial Spectra |
|
|
67 | (6) |
|
Treatment Options for Selected Highly Resistant Bacteria |
|
|
73 | (2) |
|
Suggested Management of Suspected or Culture-Positive Community-Associated Methicillin-Resistant S. Aureus (CA-MRSA) Infections |
|
|
75 | (1) |
|
Methods for Penicillin Desensitization |
|
|
76 | (1) |
|
Risk Categories of Antimicrobics in Pregnancy |
|
|
77 | (1) |
|
Selected Pharmacologic Features of Antimicrobial Agents |
|
|
78 | (5) |
|
Pharmacodynamics of Antibacterials |
|
|
82 | (1) |
|
Selected Antibacterial Agents---Adverse Reactions---Overview |
|
|
83 | (14) |
|
Antimicrobial Agents Associated with Photosensitivity |
|
|
87 | (1) |
|
Antibiotic Dosage and Side-Effects |
|
|
88 | (8) |
|
Aminoglycoside Once-Daily and Multiple Daily Dosing Regimens |
|
|
96 | (1) |
|
Treatment of Fungal Infections---Antimicrobial Agents of Choice |
|
|
97 | (15) |
|
Antifungal Drugs: Dosage, Adverse Effects, Comments |
|
|
108 | (3) |
|
At A Glance Summary of Suggested Antifungal Drugs Against Treatable Pathogenic Fungi |
|
|
111 | (1) |
|
Treatment of Mycobacterium Infections |
|
|
112 | (13) |
|
Dosage and Adverse Effects of Antimycobacterial Drugs |
|
|
122 | (3) |
|
Treatment of Parasitic Infections |
|
|
125 | (12) |
|
Dosage and Selected Adverse Effects of Antiparasitic Drugs |
|
|
134 | (2) |
|
Parasites and Cause Eosinophilia |
|
|
136 | (1) |
|
Antiviral Therapy (Non-HIV) |
|
|
137 | (31) |
|
Antiviral Drugs (Other Than Retroviral) |
|
|
148 | (4) |
|
At A Glance Summary of Suggested Antiviral Agents against Treatable Pathogenic Viruses |
|
|
152 | (1) |
|
Antiretroviral Therapy in Treatment-Naive Adults |
|
|
153 | (12) |
|
Antiretroviral Drugs and Adverse Effects |
|
|
165 | (3) |
|
Antimicrobial Prophylaxis for Selected Bacterial Infections |
|
|
168 | (10) |
|
Surgical Antibiotic Prophyalaxis |
|
|
169 | (3) |
|
Antimicrobial Prophylaxis for the Prevention of Bacterial Endocraditis in Patients with Underlying Cardiac Conditions |
|
|
172 | (1) |
|
Management of Exposure to HIV-1 and Hepatitis B and C |
|
|
173 | (3) |
|
Prevention of Opportunistic Infection in Human Stem Cell Transplantation (HSCT) or Solid Organ Transplantation (SOT) for Adults with Normal Renal Function |
|
|
176 | (2) |
|
Pediatric Dosages of Selected Antibacterial Agents |
|
|
178 | (1) |
|
Dosages of Antimicrobial Drugs in Adult Patients with Renal Impairment |
|
|
179 | (7) |
|
No Dosage Adjustment with Renal Insufficiency by Category |
|
|
186 | (1) |
|
Antimicrobials and Hepatic Disease Dosage Adjustment |
|
|
186 | (1) |
|
Treatment of CAPD Peritonitis in Adults |
|
|
186 | (1) |
|
Recommended Childhood and Adolescent Immunization Schedule in The United States 2008 |
|
|
187 | (5) |
|
Adult Immunization In the United States |
|
|
187 | (4) |
|
Anti-Tetanus Prophylaxis, wound Classification, Immunization |
|
|
191 | (1) |
|
Rabies Post-Exposure Prophylaxis |
|
|
191 | (1) |
|
Selected Directory of Resources |
|
|
192 | (1) |
|
Anti-Infective Drug-Drug Interactions |
|
|
193 | (9) |
|
Drug-Drug Interactions Between Protease Inhibitors |
|
|
200 | (1) |
|
Drug-Drug Interactions Between Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIS) and Protease Inhibitors |
|
|
201 | (1) |
|
List of Generic and Common Trade Names |
|
|
202 | (2) |
| Index of Major Entities |
|
204 | |
